Incyte (NASDAQ:INCY) Hit Lower Rating.

June 27, 2018 - By Alex Paulin

Incyte Corporation (NASDAQ:INCY) Corporate Logo

Big Money Sentiment increased to 1.22 in 2018 Q1. It has change of 0.16, from 2017Q4’s 1.06. The ratio increased due to Incyte Corporation positioning: 45 sold and 131 reduced. 57 funds took stakes and 157 increased stakes. Investors holded 191.73 million in 2017Q4 but now own 190.28 million shares or 0.76% less.

Mason Street Advisors Ltd Llc holds 0.05% of its capital in Incyte Corporation (NASDAQ:INCY) for 24,472 shs. Public Sector Pension Inv Board holds 0.02% or 39,435 shs. Aureus Asset Limited Company has invested 0.04% in Incyte Corporation (NASDAQ:INCY). Dafna Cap Mngmt Llc holds 15,000 shs or 0.61% of its capital. Cullen Frost Bankers Inc invested 0.03% of its capital in Incyte Corporation (NASDAQ:INCY). Live Your Vision Ltd Co, a Pennsylvania-based fund reported 1 shs. Schwab Charles Mngmt Inc has invested 0.04% of its capital in Incyte Corporation (NASDAQ:INCY). 2,500 were reported by Twin Focus Capital Lc. Deutsche Bancshares Ag has 1.49 million shs. Pitcairn Com, a Pennsylvania-based fund reported 5,131 shs. New York-based Grandfield And Dodd Limited Co has invested 0.07% in Incyte Corporation (NASDAQ:INCY). Lau Limited Co owns 12,532 shs for 0.81% of their capital. Vanguard Group reported 0.07% of its capital in Incyte Corporation (NASDAQ:INCY). Franklin Resource holds 0.06% of its capital in Incyte Corporation (NASDAQ:INCY) for 1.52 million shs. Moreover, Ipg Inv Advisors Ltd Llc has 0% invested in Incyte Corporation (NASDAQ:INCY).

Incyte Corporation had 4 selling transactions and 1 insider purchase since January 5, 2018. This’s net activity of $5.08 million. On Monday, April 30 SWAIN PAULA J sold $4.99M worth of Incyte Corporation (NASDAQ:INCY). $167,507 worth of Incyte Corporation (NASDAQ:INCY) was sold by Huber Reid M. GRYSKA DAVID W had sold 6,760 shs worth $668,361.

RBC Capital Mkts Lowered Incyte (NASDAQ:INCY)’s Stock Rating to “Sector Perform”.

Equities researchers at RBC Capital Mkts changed to “Sector Perform” from “Outperform” the INCY’s stock rating. On Tuesday morning the cut was issued.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Total analysts of 16 have positions in Incyte (NASDAQ:INCY) as follows: 11 rated it a “Buy”, 0 with “Sell” and 5 with “Hold”. The positive are 69%. Since January 2, 2018 according to StockzIntelligence Inc Incyte has 23 analyst reports. On Wednesday, April 4 the stock has “Buy” rating by RBC Capital Markets. On Friday, April 6 SunTrust maintained Incyte Corporation (NASDAQ:INCY) with “Buy” rating. In Friday, April 6 report William Blair downgraded the stock to “Market Perform” rating. On Tuesday, January 2 the rating was upgraded by RBC Capital Markets to “Outperform”. On Friday, April 6 Guggenheim downgraded the shares of INCY in report to “Neutral” rating. The stock rating was maintained by Credit Suisse with “Outperform” on Monday, April 9. The stock rating was reinitiated by PiperJaffray with “Overweight” on Thursday, May 31. On Tuesday, January 2 the stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given by BMO Capital Markets. On Tuesday, June 26 RBC Capital Markets downgraded Incyte Corporation (NASDAQ:INCY) rating. RBC Capital Markets has “Hold” rating and $7400 target. On Thursday, February 15 the rating was maintained by BMO Capital Markets with “Buy”.

Ticker’s shares touched $66.73 during the last trading session after 6.97% change.Incyte Corporation is downtrending after having declined 50.56% since June 27, 2017. INCY has 4.06M volume or 50.52% up from normal. The stock underperformed the S&P 500 by 63.13%.

On August, 7. Investors wait Incyte Corporation (NASDAQ:INCY) to announce its quarterly earnings, RTT reports. Analysts predict 0.00 % diference or $-0.06 from the $-0.06 EPS from 2017. After $-0.18 EPS report last quarter, Wall Street now forecasts -66.67 % EPS growth of Incyte Corporation.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States.The firm is worth $14.15 billion. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.Last it reported negative earnings. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases ; and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs.

For more Incyte Corporation (NASDAQ:INCY) news announced recently go to: 247Wallst.com, Benzinga.com, Benzinga.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Tuesday’s Biggest Winners and Losers in the S&P 500” announced on June 26, 2018, “Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility” on June 26, 2018, “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” with a publish date: June 26, 2018, “Incyte’s Jakafi successful in mid-stage study in severe form of GvHD” and the last “40 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 26, 2018.

Incyte Corporation (NASDAQ:INCY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.